The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

Rampant crime and drug use. That’s what a court has heard was witnessed outside of Ontario’s so-called safe injection sites.

Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully met the primary endpoints in its Phase 1 ...

Author Table of Contents Key Points Media Contact For general and media inquiries and to book our experts, please contact: pr ...